Classifications

• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
  • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
  • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N33/52—Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
  • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
  • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
  • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
  • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N33/66—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose

Definitions

• the invention relates to an analytical method for the selective determination of sialic acid-carrying glycolipid complexes.
• Sialic acid N-acetyl neuraminic acid
• Sialic acid can be bound as a terminal group via an oligosaccharide chain to membrane-bound sphingolipids (J. of Supramolecular Structure 9, 157-177
• gangliosides including glycosphingolipids
• the terminology of gangliosides, including glycosphingolipids, is not always unambiguous in the literature . According to Svennerholm (Comprehensive Biochemistry 18, 201/Elsevier, Amsterdam, 1970/) the se compounds can be classif ied into the groups of monosialogangliosides, disialogangliosides and trisialogangliosides.
• the hydrophobic part of gaoglioside is ceramide , which is bound to the membrane with a long unsaturated fatty acid chain. Ceramide is bound to oligosaccharides, i.e. to glucose , galactose , N-ecetyl galactosamine and sialic acid, through an amino group.
• the glycosphingolipid macromolecule has a negative charge , and this negative charge influences certain intercellular interactions . Due to the disturbances in biochemical equilibrium in tumorous organisms the intercellular interactions change whereupon the amount of glycolipid-bound sialic acid increases in the blood.
• Sialic acid can be determined, however, by enzymatic reactions, too. According to the me thod disclosed in Clin. Chim. Acta 108, 493-498 (1980) the glycoprotein is split with neur ⁇ aminidase enzyme and the liberated sialic acid is contacted with N-acetyl-neuraminic acid-aldolase enzyme to obtain pyruvate and N-acetyl-D-mannosamine .
• the resulting pyruvate is oxidised with pyruvate oxidasa into a peroxide which is converted into a coloured substance with p-chlorophenol and 4-amino-antipyrine in the presence of peroxidase, and the amount of the resulting coloured substance is determined at 505 nm.
• disease s such as arthri tis, psoriasis , ulcer, inflamma tions and gynaecological disorders, may also result in an increase of the sialic acid content of blood (J. Clin.
• the invention is based on the recognition that, at an appropriate pH and ionic strength, different metal salts are able to separate well-defined subfractions from the complicated composite of glycolipid complexes present in blood.
• sialic acid binds preferentially to differ ent glycolipid fractions, thus, by measuring the sialic acid content of the separated glycolipid subfraction or by determining the nature of the glycolipid to which sialic acid is bound conclusion can be drawn whether an increase in sialic acid level can be attributed to a tumorous process or to a benign disease (such as inflammation, arthritis, a gynaecological disorder, etc.), and in tumorous processes conclusion can be drawn on the Drobable localization of the tumor or on the existence of metastasis . It has also been observed that when utilizing certain metal salts, primarily cadmium salts, as precipitating agent one can recognize tumorous state at a much earlier stage than it was possible when applying phosphotungstic acid as precipitating agent.
• the invention relates to a method for the selective determination of sialic acid-carrying glycolipid complexes in blood, primarily in human blood, in which the serum is diluted with water, then extracted with a water-immiscible organic solvent or solvent mixture to remove neutral lipids, a lipoprotein fraction containing sialic acid-carrying glycolipids is precipitated from the aqueous phase , the precipitated fraction is redissolved, and the sialic acid content of the solution or the amount and quality of the sialic acid-carrying glycolipid is (are) determined by a method known per sa.
• a water-soluble salt of a monovalant , bivalent or trivalent metal other than alkali metal is applied as precipitating agent in an amount corresponding to a final metal ion concentration of 0.005-0.1 mole/1 in the mixture , and precipitation is performed at a pH of 1.5 to 8.0.
• the equeous methanolic supernatant (in the f ollowing: the methanolic supernatant) is processed further in the precipite tion step, whereas the lower phase which is a chloroform solution of neutral lipids is discarded.
• the precipitating agent is added to the aqueous methanolic phase or to an aliquot thereof in an amount to obtain a mixture containing 0.005-0.1 mole/l of metal ion.
• the precipitating agent is utilized preferably as an aqueous solution.
• the preferred pH value s of precipitation are listed in the table below.
• the resulting precipitate is separated and then a) the sialic acid content of the precipitate is determined by a known me thod, such as on the basis of the colour reaction produced with a mineral acid, a copper(II) salt and re sorcine as described in USP 4,342 , 567, or by the enzymatic me thod disclosed in Clin. Chim. Acta 108, 493-493 (1980) , or b) the type and amount of glycolipids bound to sialic acid are determined by a known me thod, such as by high pressure liquid chromatography as described in Clin. Chem. 22, 1516-1521 (1976) .
• the differential diagnostic value of the me thod according to the invention can be increased considerably when the sialic acid content of a blood sample of one and the same origin is determined in memori s utilizing at. least f ive differ ent metal ions, and the ratios (where the
• normal value refers to the statistically calculated non-pathologic sialic acid concentration utilizing the given me tal ion as precipitating agent) are added up. According to our experiences the value of decreases (for localized tumors) in the following order: mammary tumor - - colon tumor - ovarian tumor - head/neck tumor - adenocarcinoma - non-tumorous disease - healthy tumor-free state .
• a differential diagnostic series can be obtained when the results of the sialic acid determination according to the invention, performed ? ⁇ th at least five different metal ions , are divided with the result of a known sialic acid determination (e .g. with the result of the determination disclosed in USP 4, 342,567 in which a sialic acid content independent of the origin of sialic acid is measured) , and these quotients are added up.
• the individual quotients may also have differential diagnostic value .
• the invention is elucidated in detail by the aid of the following non-limiting examples.
• the blood samples were pre-treated and the sialic acid content of the precipitate was measured as follows :
• Venal blood was used for the determination. After blood sampling the sample was centrifuged for 15 minutes at 4000 r.p .m. , and 0.6 ml of the sample was frozen. The lipidbound sialic acid concentration of the sample stored at -20°C remains unchanged for 6 months .
• test tubes Prior to starting the analysis the test tubes were thoroughly rinsed with methanol, dried, and pre-cooled in a refrigerator. 0.2 ml of the serum sample and 0.2 ml of bidistilled water were filled into each of the test tubes, the mixture was stirred with a Vortex stirrer for 15 seconds and then placed into ice water bath (0°C) . Two parallel samples, each, were prepared from each of the sera to be examined and from the controls .
• the contents of the individual centrifuge tubes were centrifuged for 15 minutes at 4000 r.p.m., and then the supernatant was separated completely from the precipitate by decanting (the supernatant was discarded).
• Tris buffer solution was prepared by dissolving 10 mmoles of tris (hydroxymethyl) aminomethane in one litre of bidistilled water and adjusting the pH of the resulting solution to 8.6.
• resorcin reagent solution 1 ml, each, of resorcin reagent solution was added to all of the samples (standard, blank, control, test serum) .
• the resorcin reagent solution was prepared as follows : 2 g of analytically pure resorcin were dissolved in 100 ml of bidistilled water. 2.49 g of anhydrous copper(II sulfete were dissolved in 100 ml of bidistilled water.
• test tubes were placed into a 100°C water bath for exactly 10 minutes . Thereafter all of the test tubes were immediately immersed into a 0°C ice water bath and were kept there for 10 minutes . 2 ml , each, of a 85:15 v/v mixture of butyl acetate and n-butanol were introduced into the individual test tubes and the contents of the test tubes were stirred with a Vortex stirrer for 5 minutes.
• the mixtures were allowed to stand with occasional stirring , the s ⁇ mples were centrifuged f or 10 minutes at 2500 r.p .m. , and then the blue supernatants were filled from each centrifuge tube into a measuring cell. The. density of the blue colour formed doe s not change within 6 hours .
• Photome tric measurement was performed at a wavelength of 580 nm. The zero point of the photometer was adjusted for bidistilled water . Thereafter, depending on the type of the photome ter used ( single -beam or double-beam) , the measurement was performed either against the blank, or the extinction of the blank was subtracted from the measured extinction of the sample to obtain a corrected value :
• Sialic acid content was calculated by one of the following two methods :
• the sialic acid content (A) of the supernatant sample 1 ml in volume , can be determined.
• the curve gives the sialic acid content in units of ⁇ g of sialic acid/l ml of supernatant.
• the sialic acid content of the blood serum can be calculated from the formula
• Sialic acid content (mg/100 ml) A x 0.72 ,
• A is the sialic acid content of the supernatant in units of ⁇ g/ml and 0.72 is a factor which comprises the degree of dilution and the c onversion of ⁇ g to mg .
• C (ref) is the sialic acid content of the reference serum in mg/100 ml and S(raf) is the extinction of the reference serum.
• the sialic acid content of the sample to be tested can be calculated from the formula
• Sialic acid content (mg/100 ml) S(m) x F
• Serum originating from a healthy person was extracted with a mixture of chloroform and me thanol as described above .
• the methanolic supernatant was admixed in a ratio of 10:1 with a 0.5 mole/litre solution of NiCl 2 at a pH of 3 ⁇ >5 to form a precipitate , and the sialic acid content of the precipitate was measured. A vslue of 4.65 mg % was obtained.
• Serum originating from a healthy parson was extracted with a mixture of chloroform and methsnol as described above.
• the methanolic supernatant was admixed in a ratio of 10:1 with a 1.0 mole/litre solution of NiCl 2 at a. pH of 5.3 to form a precipitate, and the sialic acid content of the precipitate was measured. A vslue of 6.43 mg % was obtained.
• Serum originating from a healthy person was extracted with a mixture of chloroform and methanol as described above.
• the methanolic supernatant was admixed in a ratio of 10:1 with a 0.1 mol/litre solution of CdCl 2 at a pH of 5.9 to form a precipitate, and the sialic acid content of the precipitate was measured. A value of 11.52 mg % was obtained.
• Serum originating from a healthy person was extracted with a mixture of chloroform and me thanol as de scribed above .
• the me thanolic supernatant was admixed in a ratio of 10:1 with a 0.5 mole/li tre s olution of CdCl 2 at a pH of 5.5 to form a precipitate , and the sialic acid content of the precipitate was measured. A vslue of 10.48 mg % was obtained.
• Serum originating from a healthy person was extracted with a mixture of chloroform and methanol as described above .
• the me thanolic supernatant was admixed in a ratio of 10:1 with a 1.0 mole/litre solution of CdCl 2 at a pH of 5.3 bo form a precipitate , and the sialic acid content of the precipitate was measured. A value of 14.81 mg % was obtained.
• Serum originating from a healthy person was extracted with a mixture of chloroform and me thanol as described above .
• the me thanolic supernatant was admixed in a ratio of 10: 1 with a 0.1 mole/litre solution of FeSO 4 at a pH of 3.3 to form a precipitate , and the sialic acid c ontent of the precipitate was measured. A vslue of 9.08 mg % was obtained.
• Serum originating from a healthy person was extracted with a mixture of chloroform and methanol as described above.
• the methanolic supernatant was admixed in a ratio of 10:1 with a 0.5 mole/litre solution of FeSO 4 at a pH of 3.0 to form a precipitate, and the sialic acid content of the precipitate was measured. A value of 9.54 mg % was obtained.
• Serum originating from a healthy person was extracted with a mixture of chloroform and methanol as described above.
• the methanolic supernatant was admixed in a ratio of 10:1 with a 1.0 mole/litre solution of FeSO 4 at a pH of 2.9 to form a precipitate, and the sialic scid content of the precipitate was measured. A value of 9.52 mg % was obtained.
• Serum originating from a healthy person was extracted with a mixture of chloroform and methanol as described above.
• the methanolic supernatant was admixed in a ratio of 10:1 with a 0.1 mole/litre solution of ZnCl 2 at a pH of 2.7 to form a precipitate, and the sialic acid content of the precipitate was measured. A value of 6.52 mg % was obtained.
• Serum originating from a heslthy person was extracted with a mixture of chloroform and methsnol as described above.
• the methanolic supernatant was admixed in a ratio of 10:1 with a 0.5 mole/litre solution of ZnCl 2 at a pH of 1.9 to form a precipitste, and the sialic acid content of the precipitate was measured. A value of 12.34 mg % was obtained.
• Serum originating from a healthy person was extracted with a mixture of chloroform end me thanol as described above .
• the me thanolic supernatant was admixed in a ratio of 10: 1 with a 0.1 mole/litre solution of Pb (NO 3 ) 2 at a pH of 4.4 to form a precipitate , and the sialic acid content of the precipitate was measured. A vslue of 8.61 mg % was obtained.
• Serum originating from a healthy person was extracted with a mixture of chloroform and me thanol as de scribed above .
• the me thanolic supernatant was admixed in a ratio of 10:1 with a 0.5 mole/litre solution of ⁇ b (NO 3 ) 2 at a pH of 3.7 to form a pre cipitate , and the sialic acid content of the precipitate was measured. A value of 12.11 mg % was obtained.
• Serum origins ting from a healthy person was extracted with a mixture of chloroform and me thanol as described above .
• the me thanolic supernatant was admixed in a ratio of 10:1 with a 1.0 mole/litre solution of Pb (NO 3 ) 2 at a pH of 3.5 to form a precipitate , and the sialic acid content of the precipitate was measured. A value of 12.35 mg % was obtained.
• Serum originating from a healthy person was extracted with a mixture of chlorof orm and me thanol as described above .
• the me thanolic supernatant was admixed in a ratio of 10: 1 with a 0.1 mole/litre solution of AgNO 3 at a pH of 8.5 to form a precipitate and the sialic ac id content of the precipitate was measured. A value of 9.89 mg % was obtained.
• Serum originating from a healthy person was extracted with a mixture of chloroform and methanol as described above.
• the methanolic supernatant was admixed in a ratio of 10:1 with a 0.5 mole/litre solution of AgNO 3 at a pH of 6.0 to form a precipitate , and the sialic acid content of the precipitate was measured. A value of 14.67 mg % was obtained.
• Serum originating from a healthy person was extracted with a mixture of chloroform and me thanol as described above .
• the methanolic supernatant was admixed in s ratio of 10: 1 with a 1.0 mole/litre solution of AgNO 3 at a pH of 5.8 to form a precipitate , and the sialic acid content of the precipitate was measured. A value of 14.81 mg % was obtained.
• Serum originating from a healthy person was extracted with a mixture of chloroform end methanol as described above .
• the methanolic supernstant was sdmixed in a ratio of 10: 1 with a 0.1 mole/litre solution of HgCl 2 at a pH of 1.9 to form a precipitate , and the sialic acid content of the precipitate was measured. A value of 6.05 mg % was obtained.
• Serum originating from a healthy person was extracted with a mixture of chloroform and methanol as described above.
• the methanolic supernatant was admixed in a ratio of 10:1 with a 0 ,3 mole/litre solution of HgCl 2 at a pH of 1.7 to form a precipitate, and the sialic acid content of the precipitate was measured. A value of 7.68 mg % was obtained.
• Serum originating from a healthy person was extracted with a mixture of chloroform and me thanol as described above .
• the me thanolic supernatant was admixed in a ratio of 10: 1 with a 1.0 mole/litre solution of HgCl 2 at a pH of 1.5 to f orm a precipitate , and the sialic acid c ontent of the precipitate was measured. A value of 11.99 mg % was obtained.
• Serum originating from a healthy person was extracted . with a mixture of chloroform end methanol as described above.
• the me thanolic supernatant was admixed in a ratio of 10:1 with a 0.1 mole/litre solution of CuSO 4 at a pH of 4.2 to form a precipitate , and the sialic acid content of the precipitate was measured .
• a value of 10.13 mg % was ob tained.
• Serum originating from a healthy person was extracted with a mixture of chloroform and me thanol as described above.
• the me thanolic supernstant was admixed in a ratio of 10: 1 with a 0.5 mole/litre solution of CuSO 4 at a pH of 3.8 to form a precipitate , and the sialic acid content of the precipitate was measured. A value of 10.48 mg % was obtained.
• Serum ori ginating from a healthy person was extracted with a mixture of chloroform and me thanol as de scribed above.
• the me thanolic supernatant was admixed in a ratio of 10: 1 with a 1,0 mole/litre solution of CuSO 4 at a pH of 3.6 to form a pre cipitate , and the sialic acid content of the prec ipitate was measured. A value of 12.22 mg % was obtained.
• Serum originating from a healthy person was extracted with a mixture of chloroform and methanol as described above.
• the methanolic supernatant was admixed in a ratio of 10:1 with a 0.1 mole/litre solution of CaCl 2 at a pH of 5.5 to form a precipitate, and the sialic acid content of the precipitate was measured. A value of 3.72 mg % was obtained.
• Serum originating from a healthy person was extracted with a mixture of chloroform and methanol as described above.
• the methanolic supernatant was admixed in a ratio of 10:1 with a 0.5 mole/litre solution of CaCl 2 at a pH of 5.4 to form a precipitate, and the sialic acid content of the precipitate was measured. A value of 3.02 mg % was obtained.
• Serum originating from a healthy person was extracted with a mixture of chloroform and methanol as described above.
• the methanolic supernatant was admixed in a ratio of 10:1 with a 1.0 mole/litre solution of CaCl 2 at a pH of 5.3 to form a precipitate, and the sialic acid content of the precipitate was measured. A value of 7.05 mg % was obtained.
• Serum originating from a healthy person was extracted with a mixture of chloroform and methanol as described above.
• the methanolic supernatant was admixed in a ratio of 10:1 with a 0.1 mole/litre solution of MgCl 2 at a pH of 6.1 to form a precipitate, and the sialic acid content of the precipitate was measured. A value of 4.19 mg 55 was obtained.
• Example 27
• Serum originating from a healthy person was extracted with a mixture of chloroform and methanol as described above
• the methsnolic supernatant was admixed in a ratio of 10:1 with a 0.5 mole/litre solution of MgCl 2 at a pH of 6.7 to form a precipitate, and the sialic acid content of the precipitate was measured. A value of 3.61 mg % was obtained.
• Serum originating from a healthy person was extracted with a mixture of chloroform and methanol as described above
• the methanolic supernatant was admixed in a ratio of 10:1 with a 1.0 mole/litre solution of MgCl 2 st a pH of 6.5 to form a precipitate, and the sialic scid content of the precipitate was measured. A value of 4.81 mg % was obtained.
• Serum originating from s patient with mammary cancer was extracted with a mixture of chloroform and methanol as described above.
• the methanolic supernatant was admixed in a ratio of 10:1 with a 1.0 mole/litre solution of NiCl 2 at a pH of 5.3 to form a precipitate, and the sialic acid content of the precipitate was measured.
• Serum originating from a patient with mammary cancer was extracted with a mixture of chloroform and methanol as described above.
• the methanolic supernatant was admixed in a ratio of 10:1 with s 1.0 mole/litre solution of CdCl 2 at a pH of 5.3 to form a precipitate, and the sialic acid Content of the prec ipitate was measured.
• Serum originating from a patient with mammary cancer was extracted with a mixture of chloroform and methanol as described above .
• the methanolic supernatant was admixed in a ratio of 10:1 with a 1.0 mole/litre solution of FeSO ⁇ at a pH of 2.9 to form a precipitate , and the sialic acid content of the precipitate was measured.
• Serum originating from a patient with mammary cancer was extracted with a mixture of chloroform and methanol as described above .
• the methanolic supernatant was admixed in a ratio of 10:1 with a 1.0 mole/litre solution of ZnCl 2 at a pH of 1.7 to form a precipitate , and the sialic acid content of the precipitate was measured.
• Serum originating from a patient with mammary cancer was extracted with a mixture of chloroform and methanol as described above .
• the methanolic supernatant was admixed in a ratio of 10:1 with a 1.0 mole/litre solution of ZnSO 4 at a pH of 1.7 to form a precipitate , and the sialic acid content of the precipitate was measured.
• Serum originating from a patient with mammary cancer was extracted with a mixture of chloroform and methanol as described above .
• the me thanolic supernatant was admixed in a ratio of 10:1 with a 1.0 mole/litre solution of Pb (NO 3 ) 2 at a pH of 3.5 to form a precipitate , and the sialic acid content of the precipitate was measured.
• Serum originating from a patient with mammary cancer was extracted with a mixture of chloroform and methanol as described above .
• the methanolic supernatant was admixed in a ratio of 10:1 with a 1.0 mole/litre solution of AgNO 3 at a pH of 5.8 to form a precipitate , and the sialic acid content of the precipitate was measured.
• Serum originating from a patient with mammary cancer was extracted with a mixture of chloroform and me thanol as described above .
• the methanolic supernatant was admixed in a rstio of 10: 1 with s 1.0 mole/litre solution of HgCl 2 a t a pH of 1.5 to form a pre cipitate , and the sialic acid content of the precipitate was measured.
• Serum originating from a pa tient with mammary cancer was ex trac ted with a mix ture of chloroform and methanol as described above .
• the methanolic supernatant was admixed in a ratio of 10:1 with a 1.0 mole/litre solution of CuSO 4 at a pH of 3.6 to form a precipitate , and the sialic acid content of the precipitate was measured.
• Serum originating from a patient with mammary cancer was extracted with a mixture of chloroform and metha nol as described above .
• the me thanolic supernatant was admixed in a ratio of 10: 1 with a 1.0 mole/litre solution of CaCl 2 at a pH of 5.3 to form a precipitate , and the sialic acid content of the precipitate was measured.
• Serum originating from a patient with mammary cancer was extracted with a mixture of chloroform and me thanol as described above .
• the methanolic supernatant was admixed in a rstio of 10:1 with a 1.0 mole/litre solution of MgCl 2 at a pH of 6.5 to form a precipita te , and the sialic acid content of the precipitate was measured.
• Serum originating from a patient with ovarian cancer was extracted with a mixture of chloroform and methanol as described above .
• the methanolic supernatant was admixed in a ratio of 10:1 with a 1.0 mole/litre solution of NiCl 2 at a pH of 5.3 to f orm a precipitate , and the sialic acid content of the precipita te was measured.
• Serum originating from a patient with ovarian cancer was extracted with a mixture of chloroform and methanol as described above.
• the methanolic supernatant was admixed in a ratio of 10:1 with a 1.0 mole/litre solution of CdCl 2 at a pH of 5.3 to form a precipitate, and the sialic acid content of the precipitate was measured.
• Serum originating from a patient with ovarian cancer was extracted with a mixture of chloroform and me thanol. as described above .
• the methanolic supernatant was admixed in a ratio of 10:1 with a 1.0 mole/litre solution of FeSO 4 at a pH of 2.9 to form a precipitate , and the sialic a cid content of the precipitate was measured.
• Serum originating from a patient with ovarian cancer was extracted with a mixture of chloroform and methanol as described above .
• Serum originating from a patient with ovarian ca ncer was extracted with a mixture of chloroform and me thanol as described above .
• the me thanolic supernatant was admixed in a ratio of 10:1 with a 1.0 mole/litre solution of ZnSO 4 at a pH of 1.7 to form a precipitate , and the sialic acid content of the precipitate was measured.
• Serum originating from a pa tient with ovarian cancer was extracted with a mixture of chloroform and me thanol as described above .
• the methanolic supernatant was admixed in a ratio of 10:1 with a 1.0 mole/litre solution of Pb ( NO 3 ) 2 at a pH of 3.5 to form a precipitate , end the sialic acid content of the precipitate was measured.
• Serum originating from a patient with ovarian cancer was extracted with a mixture of chloroform and methanol as described above .
• the methanolic supernatant was admixed in a ratio of 10:1 with a 1.0 mole/litre solution of Ag NO 3 at a pH of 5.8 to form a precipita te , and the sialic acid content of the precipitate was measured.
• the methanolic supernatant was admixed in a ratio of 10: 1 with a 1.0 mole/litre solution of HgCl 2 at a pH of 1.5 to form a precipitate , and the sialic acid content of the precipitate was measured.
• Serum originating from a patient with ovarian cancer was extracted with a mixture of chloroform and methanol as described above .
• the me thanolic superna tant was admixed in a ratio of 10 :1 with a 1.0 mole/litre solution of CuSO 4 at a pH of 3.6 to form a precipitate , and the sialic acid content of the precipitate was measured.
• Serum originating from a patient with ovarian cancer was extracted with s mixture of chloroform and me thanol as described above .
• the methanolic supernatant was admixed in a ratio of 10: 1 with a 1.0 mole/litre solution of CaCl 2 at a pH of 5.3 to form a precipitate , and the sialic acid content of the precipitate was measured.
• Serum originating from a patient with ovarian cancer was extracted with a mixture of chloroform and methanol as described above .
• the me tha nolic superna tant was admixed in a ratio of 10 : 1 with a 1.0 mole/litre so lution of MgCl 2 at a pH of 6.5 to f orm a precipitate , and the sialic a cid content of the precipita te was measured.
• Serum originating from a pa tient with head/neck cancer was extracted with a mixture of chloroform and me thanol as described above .
• the me thanolic supernatant was admixed in a ratio of 10:1 with a 1.0 mole/litre solution of MC1 2 at a pH of 5.3 to form a precipitate , and the sialic acid content of the precipitate was measured.
• Serum originating from a patient with head/neck cancer was extracted with a mixture of chloroform and me thanol as described above .
• the methanolic suparnatant was admixed in a ra tio of 10 :1 with a 1.0 mole/litre solution of CdCl 2 at a pH of 5.3 to form a precipitate , and the sialic acid content of the pre cipitate was measured.
• Serum origina ting from a patient with head/neck cancer was extracted with a mixture of chloroform and methanol as described above .
• Serum originating from a patient with head/neck cancer was extracted with a mixture of chloroform and methanol as described above .
• the methanolic supernatant was admixed in a ratio of 10:1 with a 1.0 mole/litre solution of ZnCl 2 at a pH of 1.7 to form a precipitate , and the sialic acid content of the precipitate was measured .
• Serum originating from a patient with head/neck cancer was extracted with a mixture of chloroform and methanol as described above .
• the methanolic supernatant was admixed in a ratio of 10:1 with a 1.0 mole/litre solution of ZnSO 4 at a pH of 1.7 to form a precipitate , and the sialic acid content of the precipitate was mes sured.
• Serum originating from a patie nt with head/neck cancer was extracted with a mixture of chloroform and methanol as de scribed above .
• the methanolic supernatant was admixed in a ratio of 10:1 with a 1.0 mole/litre solution of Pb(NO 3 ) 2 at a pH of 3.5 to form a precipitate , and the sialic acid content of the precipitate was measured.
• Serum originating from a patient with head/neck cancer was extracted with a mix ture of chloroform and methanol as described above .
• the methanolic supernatant was admixed in a ratio of 10: 1 with a 1.0 mole/litre solution of Ag NO 3 at a pH of 5.8 to form a precipitate , and the sialic acid content of the precipitate was measured.
• Serum originating from a patient with head/neck cancer was extracted with a mixture of chloroform and methanol as described above .
• the methanolic supernatant was admixed in a ratio of 10:1 with a 1.0 mole/litre solution of HgCl 2 at a pH of 1.5 to form a precipitate , and the sialic acid content of the precipitate was measured.
• Serum originating from a patient with head/neck cancer was extracted with a mixture of chloroform and methanol as described above .
• the methanolic supernatant was admixed in a ratio of 10 :1 with a 1.0 mole/litre solution of CuSO 4 at a pH of 3.6 to form a precipitate , and the sialic acid content of the precipitate was measured.
• Serum originating from a patient with head/neck cancer was extracted with a mixture of chloroform and me thanol as described above .
• the methanolic supernatant was admixed in a ratio of 10:1 with a 1.0 mole/litre solution of CaCl 2 at a pE of 5.3 to form a precipitate , and the sialic acid content of the pre cipitate was measured.
• Serum originating from a patient with head/neck cancer was extracted with a mixture of chloroform and methanol as described above .
• the methanolic supernatant was admixed in a ratio of 10: 1 with a 1.0 mole/litre solution of MgCl 2 at a pH of 6.5 to form a precipitate , and the sialic acid content of the precipitate was measured.
• Serum originating from a patient with a denocarcinoma was extracted with a mixture of chloroform and methanol as described above .
• the methanolic supernatant was admixed in a ratio of 10: 1 with a 1.0 mole/litre solution of NiCl 2 at a pH of 5.3 to form a precipitate , and the sialic acid content of the precipitate was measured.
• Serum originating from a patient with adenocarcinoma was extracted with a mixture of chloroform and me thanol as described above .
• the methanolic supernatant was admixed in a ratio of 10:1 with a 1.0 mole/litre solution of CdCl 2 at a pH of 5.3 to form a precipitate , and the sialic acid content of the precipitate was measured.
• Serum originating from a patient with a denocarcinoma was extracted with a mixture of chloroform and methanol as described above .
• the methanolic supernatant was admixed in a ratio of 10: 1 with a 1.0 mole/litre solution of FeSO 4 at a pH of 2.9 to form a precipitate , and the sialic acid content of the precipitate was measured.
• Serum originating from a patient with adenocarcinoma was extracted with a mixture of chloroform and methanol as described above.
• the methanolic supernatant was admixed in a ratio of 10:1 with a 1.0 mole/litre solution of ZnCl 2 at a pH of 1.7 to f orm a precipitate , and the sialic acid content of the precipitate was measured.
• Serum originating from a patient with adenocarcinoma was extracted with a mixture of chloroform and methanol as described above .
• the methanolic supernatant was admixed in a ratio of 10 :1 with a 1.0 mole/litre solution of ZnSO 4 at a pH of 1.7 to form a precipitate , and the sialic acid content of the precipitate was measured.
• Serum originating from a patient with adenocarcinoms was extracted with a mixture of chloroform and methanol as described above .
• the methanolic supernatant was admixed in a ratio of 10: 1 with a 1.0 mole/litre soluti on of Pb (NO 3 ) 2 at a pH of 3.5 to form a precipitate , and the sialic acid content of the precipitate was measured.
• Serum originating from a patient with adenocarcinoma was extracted with a mixture of chloroform and methanol as described above .
• the methanolic supernatant was admixed in a ratio of 10: 1 with a 1.0 mole/litre solution of AgNO 3 at a pH of 5.8 to f orm a pre cipitate , and the sialic acid content of the precipitate was measured.
• Serum originating from a patient with adenocarcinoma was extracted with a mixture of chloroform and methanol as described above .
• the methanolic supernatant was admixed in a ratio of 10 :1 with a 1.0 mole/litre solution of HgCl 2 at a pH of 1.5 to form a precipitate , and the sialic acid content of the precipitate was measured.
• Serum originating from a patient with adenocarcinoma was extracted with a mixture of chloroform and me thanol as described above .
• the me thanolic supernatant was admixed in a ratio of 10:1 with a 1.0 mole/litre solution of CuSO 4 at a pH of 3.6 to form a precipitate , and the sialic acid content of the precipitate was measured.
• Serum originating from a patient with adenocarcinoma was extracted with a mixture of chloroform and methanol as described above .
• the methanolic supernatant was admixed in a ratio of 10: 1 with a 1.0 mole/litre solution of CaCl 2 at a pH of 5.3 to form a precipitate , and the sialic acid content of the precipitate was measured.
• Serum originating from a patient with adenocarcinoma was extracted with a mixture of chloroform and methanol as described above .
• the methanolic supernatant was admixed in a ratio of 10 :1 with a 1.0 mole/litre solution of MgCl 2 at a pH of 6.5 to form a precipitate , and the sialic acid content of the precipitate was measured.
• Serum originating from a patient with colon cancer was extracted with a mixture of chloroform and methanol as described above .
• the me thanolic supernatant was admixed in a ratio of 10:1 with a 1.0 mole/litre solution of NiCl 2 at a pH of 5.3 to f orm a pre cipitate , and the sialic acid content of the precipitate was measured.
• Serum originating from a patient with colon cancer was extracted with a mixture of chloroform and me thanol as de scribed above .
• the me thanolic supernatant was admixed in a ratio of 10 : 1 with a 1.0 mole/litre solution of CdCl 2 st a pH of 5.3 to form a precipitate , and the sialic acid content of the precipitate was measured.
• Serum originating from a patient with colon cancer was extracted with a mixture of chloroform and methanol as described above .
• the me thanolic supernatant was admixed in a ratio of 10: 1 with a 1.0 mole/litre s olution of FeSO 4 at a pH of 2.9 to form a precipitate , and the sialic acid content of the precipitate was measured.
• Serum originating from a patient with colon cancer was extracted with a mixture of chloroform and me thanol as described above.
• the methanolic supernatant was admixed in a ratio of 10:1 with a 1.0 mole/litre solution of ZnCl 2 at a pH of 1.7 to form a precipitate , and the sialic acid conte nt of the precipitate was measured .
• Serum originating from a patient with colon cancer was extrac ted with a mixture of chlorof orm and methanol as described above .
• the methanolic supernatant was admixed in a ratio of 10: 1 with a 1.0 mole/litre solution of ZnSO 4 at a pH of 1.7 to form a precipitate , and the sialic acid content of the precipitate was measured.
• Serum originating from a patient with colon cancer was extracted with a mixture of chloroform and methanol as described above .
• the methanolic supernatant was admixed in a ratio of 10 :1 with a 1.0 mole/litre solution of Pb ( NO 3 ) 2 at a pH of 3.5 to form a pre cipitate , and the sialic acid content of the precipitate was measured.
• Serum originating from a patient with colon cancer was extracted with a mixture of chloroform and methanol as described above .
• the methanolic supernatant was admixed in a ratio of 10:1 with a 1.0 mole/litre solution of AgNO 3 at a pH of 5.8 to form a precipitate , and the sialic acid content of the precipitate was measured.
• Serum origins ting from a patient with colon cancer was extracted with a mixture of chloroform and methanol as described above.
• the methanolic supernatant was admixed in a ratio of 10: 1 with a 1.0 mole/litre solution of HgCl 2 at s pH of 1.5 to form a precipitate , and the siolic acid content of the precipitate was measured.
• Serum originating from s patient with colon cancer was extracted with a mixture of chloroform and methanol as described above .
• the me thanolic supernatant was admixed in a ratio of 10: 1 with a 1.0 mole/litre solution of CuSO 4 at a pH of 3.6 to form a precipitate , and the sialic acid content of the precipitate was measured.
• Serum originating from a patient with colon cancer was extracted wi th a mix ture of chloroform and me thanol as de scribed above .
• the me thanolic supernatant was admixed in a ratio of 10: 1 with a 1.0 mole/litre solution of CaCl 2 at a pH of 5.3 to form a precipitate , and the sialic acid content of the precipitate was measured.
• Serum originating from a patient with colon cancer was extrac ted with a mixture of chloroform and me thanol as described above .
• the me thanolic supernatant was admixed in a ratio of 10:1 with a 1.0 mole/litre solution of MgCl 2 at a pH of 6.5 to form a precipitate , and the sialic acid content of the precipitate was measured.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Engineering & Computer Science (AREA)
• Hematology (AREA)
• Immunology (AREA)
• Molecular Biology (AREA)
• Urology & Nephrology (AREA)
• Biomedical Technology (AREA)
• Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Physics & Mathematics (AREA)
• Microbiology (AREA)
• Pathology (AREA)
• Cell Biology (AREA)
• Food Science & Technology (AREA)
• Biotechnology (AREA)
• General Physics & Mathematics (AREA)
• Analytical Chemistry (AREA)
• Biochemistry (AREA)
• General Health & Medical Sciences (AREA)
• Endocrinology (AREA)
• Biophysics (AREA)
• Diabetes (AREA)
• Investigating Or Analysing Biological Materials (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Applications Claiming Priority (4)

Publications (1)

Family

ID=26317184

Family Applications (1)

Country Status (10)

Family Cites Families (1)

• 1989
  • 1989-05-12 KR KR1019900701970A patent/KR910700457A/ko not_active Application Discontinuation
  • 1989-05-12 WO PCT/HU1989/000021 patent/WO1990008317A1/en not_active Application Discontinuation
  • 1989-05-12 EP EP89905744A patent/EP0515355A1/en not_active Ceased
  • 1989-05-12 AU AU37356/89A patent/AU3735689A/en not_active Abandoned
  • 1989-05-26 JP JP1131718A patent/JPH02206763A/ja active Pending
  • 1989-06-06 ES ES8901972A patent/ES2012728A6/es not_active Expired - Fee Related
  • 1989-06-20 CN CN89104207A patent/CN1044537A/zh active Pending
• 1990
  • 1990-09-05 NO NO1990903877A patent/NO903877D0/no unknown
  • 1990-09-20 DK DK226590A patent/DK226590A/da not_active Application Discontinuation
• 1991
  • 1991-07-23 FI FI913518A patent/FI913518A0/fi not_active Application Discontinuation

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events